Research ArticleDrug Discovery and Translational Medicine
Characterization of the Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 ADX88178 in Rodent Models of Neuropsychiatric Disorders
Mikhail Kalinichev, Emmanuel Le Poul, Christelle Boléa, Françoise Girard, Brice Campo, Massimiliano Fonsi, Isabelle Royer-Urios, Susan E. Browne, Jason M. Uslaner, Matthew J. Davis, Jacob Raber, Robert Duvoisin, Simon T. Bate, Ian J. Reynolds, Sonia Poli and Sylvain Celanire
Journal of Pharmacology and Experimental Therapeutics September 2014, 350 (3) 495-505; DOI: https://doi.org/10.1124/jpet.114.214437
Mikhail Kalinichev
Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.)
Emmanuel Le Poul
Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.)
Christelle Boléa
Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.)
Françoise Girard
Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.)
Brice Campo
Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.)
Massimiliano Fonsi
Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.)
Isabelle Royer-Urios
Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.)
Susan E. Browne
Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.)
Jason M. Uslaner
Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.)
Matthew J. Davis
Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.)
Jacob Raber
Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.)
Robert Duvoisin
Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.)
Simon T. Bate
Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.)
Ian J. Reynolds
Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.)
Sonia Poli
Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.)
Sylvain Celanire
Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.)

JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleDrug Discovery and Translational Medicine
mGlu4 PAM ADX88178 in Models of Neuropsychiatric Disorders
Mikhail Kalinichev, Emmanuel Le Poul, Christelle Boléa, Françoise Girard, Brice Campo, Massimiliano Fonsi, Isabelle Royer-Urios, Susan E. Browne, Jason M. Uslaner, Matthew J. Davis, Jacob Raber, Robert Duvoisin, Simon T. Bate, Ian J. Reynolds, Sonia Poli and Sylvain Celanire
Journal of Pharmacology and Experimental Therapeutics September 1, 2014, 350 (3) 495-505; DOI: https://doi.org/10.1124/jpet.114.214437
Research ArticleDrug Discovery and Translational Medicine
mGlu4 PAM ADX88178 in Models of Neuropsychiatric Disorders
Mikhail Kalinichev, Emmanuel Le Poul, Christelle Boléa, Françoise Girard, Brice Campo, Massimiliano Fonsi, Isabelle Royer-Urios, Susan E. Browne, Jason M. Uslaner, Matthew J. Davis, Jacob Raber, Robert Duvoisin, Simon T. Bate, Ian J. Reynolds, Sonia Poli and Sylvain Celanire
Journal of Pharmacology and Experimental Therapeutics September 1, 2014, 350 (3) 495-505; DOI: https://doi.org/10.1124/jpet.114.214437
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement